Japan’s Ministry Reviews Thalidomide For Multiple Myeloma
This article was originally published in PharmAsia News
Executive SummaryThe Ministry of Health, Labor and Welfare began a review panel meeting Aug. 26 to consider thalidomide as a treatment for multiple myeloma, on condition that adverse event prevention methods are fully addressed. The MHLW panel will consider safety measures put forth by pharmaceutical companies, such as registration requirements for pharmacists, physicians and patients and establishment of a third party to monitor compliance. Upon completion of the review the drug could be launched as early as the end of the year. Japan has 13,000-14,000 multiple myeloma patients. Thalidomide is approved to treat multiple myeloma in 17 countries. (Click here for more - Japanese language)
You may also be interested in...
Philips Expert Urges Device Makers: Update Quality Systems To Conform To Revised Risk Standard ISO 14971
It’s time for manufacturers to begin adopting the new 2019 version of ISO 14971, the international standard for risk management widely used by industry. But firms need to do more work than just changing the date on risk-related procedures and documents to “2019,” says Jos Van Vroonhoven, a senior manager at Philips Healthcare who was intimately involved with the standard’s redo. From conducting gap assessments to creating cross-functional teams, both Van Vroonhoven and longtime industry expert Don Powers tell Medtech Insight how firms can keep their quality systems up-to-date to conform to ISO 14971:2019.
Here’s a crosswalk for recently revised international risk management standard ISO 14971 and its 2007 predecessor.